• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: W. L. GORE & ASSOCIATES, INC. GORE® VIABAHN® ENDOPROSTHESIS WITH HEPARIN BIOACTIVE SURFACE; STENT, SUPERFICIAL FEMORAL ARTERY

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

W. L. GORE & ASSOCIATES, INC. GORE® VIABAHN® ENDOPROSTHESIS WITH HEPARIN BIOACTIVE SURFACE; STENT, SUPERFICIAL FEMORAL ARTERY Back to Search Results
Device Problem Complete Blockage (1094)
Patient Problem Obstruction/Occlusion (2422)
Event Date 08/28/2022
Event Type  Injury  
Manufacturer Narrative
This information was obtained by gore from a conference presentation (the 17th japan endovascular symposium; august 28, 2022).Title of the presentation: a case of acute limb ischemia due to extensive thrombotic occlusion of eia~pop immediately after stent-graft implantation for sfa occlusion with intermittent claudication.The serial numbers remain unknown and no devices were returned.Additional information regarding the event and devices was asked, but was not made available to gore, therefore this investigation is considered complete with the information available.The patient identifier (internal gore id: 00010413) is associated with two other devices/mdrs involved within this event.Cbas® heparin surface incorporates carmeda heparin manufactured from heparin sodium api, which is covalently bound to the device surface and is essentially non-eluting.
 
Event Description
The following information was obtained by gore from a conference presentation: the patient underwent endovascular treatment for long occlusion in the right superficial femoral artery (sfa) with intermittent claudication that had appeared approximately 1 month ago using two gore® viabahn® endoprostheses with heparin bioactive surface (viabahn device).The viabahn devices were implanted from about 4-5 mm distal to the origin of the sfa.After the implantation, digital subtraction angiography (dsa) showed a suspected defect at the origin of the sfa.Thrombus aspiration was performed, but the defect was confirmed to be worsened by dsa, and ivus revealed the suspicion of residual plaque at the origin of the sfa, so a non-gore stent was implanted at the site.Dsa showed that the defect had migrated to the cfa and the lateral femoral circumflex artery (lfca) was poorly visualized.Ivus showed flattening of the proximal edge of the non-gore stent and stenosis at the distal cfa.Aspiration was performed and lcfa visual got improved but sfa became stenosed.After repeated poba, cfa stenosis improved to 50%, but a 5-6 cm stenosis appeared at the proximal sfa, so an additional viabahn device was implanted at the site.However, the sfa including the viabahn devices were poorly visualized.Poba was performed, and although there was a 50% stenosis of the cfa, the sfa became patent, so the treatment was moved to anticoagulation therapy.Pain and numbness in the right leg began at night, and the next morning, right leg paresthesia and dyskinesia appeared.Mra showed extensive occlusion from the right distal external iliac artery to p2, and all three viabahn devices showed occlusion.Emergency surgery was performed to remove the proximal and distal thrombus and a femoro-popliteal bypass.The patient was discharged 23 days postoperatively.The removed thrombus was confirmed to be a ¿hard¿ (non-collapsible) thrombus with a slightly white tone, so a plaque shift was suspected.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
GORE® VIABAHN® ENDOPROSTHESIS WITH HEPARIN BIOACTIVE SURFACE
Type of Device
STENT, SUPERFICIAL FEMORAL ARTERY
Manufacturer (Section D)
W. L. GORE & ASSOCIATES, INC.
1505 n. fourth street
flagstaff AZ 86004
Manufacturer (Section G)
MEDICAL ECHO RIDGE B/P
3250 w. kiltie lane
flagstaff AZ 86005
Manufacturer Contact
kaitlin barnash
1505 n. fourth street
flagstaff, AZ 86004
9285263030
MDR Report Key15396674
MDR Text Key299666300
Report Number2017233-2022-03303
Device Sequence Number1
Product Code NIP
Combination Product (y/n)Y
Reporter Country CodeJA
PMA/PMN Number
P040037
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Other
Reporter Occupation Physician
Type of Report Initial
Report Date 09/09/2022
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Initial Date Manufacturer Received 08/28/2022
Initial Date FDA Received09/09/2022
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Required Intervention; Other;
Patient Age73 YR
Patient SexFemale
-
-